N-formyl-N-methylaminoacetyldimethylamide | 117122-62-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-formyl-N-methylaminoacetyldimethylamide
• 英文别名: N-Formyl-sarkosin-dimethylamid；N-Formyl-N-methyl-aminoessigsaeure-dimethylamid；2-[formyl(methyl)amino]-N,N-dimethylacetamide
• CAS: 117122-62-0
• 化学式: C₆H₁₂N₂O₂
• 分子量: 144.173
• InChiKey: DQZVQVUPVGBANY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N,N-二甲基甲酰胺 在 二叔丁基过氧化物 作用下， 生成 N-formyl-N-methylaminoacetyldimethylamide
  参考文献：
  名称：

  Amidation and aminoalkylation of olefins: Blocking techniques in radical chain reactions

  摘要：

  DOI：

  10.1016/s0040-4039(01)84053-3

文献信息

• Tricyclic delta-opioid modulators
  申请人：Dax Scott

  公开号：US20060030585A1

  公开（公告）日：2006-02-09

  The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

  这项发明涉及δ阿片受体调节剂。更具体地，该发明涉及三环δ-阿片调节剂。还描述了利用该发明的化合物治疗轻度至严重疼痛和各种疾病的药用和兽医组合物以及方法。
• Radical production evidenced by dimer analysis in γ-irradiated amides in aqueous solutions and in the solid state
  作者：Anne-Catherine Dusaucy、Joëlle de Doncker、Christine Couillard、Marc de Laet、Bernard Tilquin

  DOI：10.1039/f19878300125

  日期：——

  formation. In the solid state the radiolytic formation of radicals is selective. Final product analysis by capillary gas chromatography and the direct study of radicals by pulse radiolysis are also complementary methods for studying the nature of radicals produced from the radiolysis of amides in aqueous solutions. The selective production of one parent radical is characteristic of dilute solutions.

  通过两种互补的方法，对酰胺固态分解产生的自由基的性质和分布进行了研究：（i）通过毛细管气相色谱分析最终产物，以及（ii）通过电子自旋共振直接观察自由基光谱学。为二聚物的异构体分布Ñ -methylformamide（NMF），Ñ甲基乙酰胺（NMA）和Ñ，Ñ-二甲基甲酰胺（DMF）允许人们通过使用二聚体形成的统计规则来估计母体自由基的分布。在固态中，自由基的辐射分解形成是选择性的。通过毛细管气相色谱法进行最终产物分析以及通过脉冲辐射分解直接研究自由基也是研究由酰胺在水溶液中辐射分解产生的自由基的性质的补充方法。选择性产生一个母体基团是稀溶液的特征。
• [EN] COMPOUNDS<br/>[FR] COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2005080360A1

  公开（公告）日：2005-09-01

  Compounds of Formula (I) wherein: R1 is methyl; R2 is selected from -C (O) NR4R5, SO2NR4R5, S (O) pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C) alkyl and HET-2; R5 is hydrogen or (1-4C) alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them and processes for their preparation are also described.

  分子式为（I）的化合物，其中：R1为甲基；R2选自-C（O）NR4R5，SO2NR4R5，S（O）pR4和HET-2；HET-1是一个5或6元环的、可选地取代的C-连接的杂芳基环；HET-2是一个4、5或6元环的、C-或N-连接的、可选地取代的杂环基环；R3选自卤素、氟甲基、二氟甲基、三氟甲基、甲基、甲氧基和氰基；R4选自氢、可选地取代的（1-4C）烷基和HET-2；R5为氢或（1-4C）烷基；或者R4和R5与它们所连接的氮原子一起可以形成由HET-3定义的杂环基环系统；HET-3例如是一个可选地取代的N-连接的、4、5或6元环的、饱和或部分不饱和的杂环基环；p是（在每次出现时）独立地为0、1或2；m为0或1；n为0、1或2；但当m为0时，则n为1或2；或其盐、前药或溶剂。还描述了它们作为GLK活化剂的用途、含有它们的制药组合物以及它们的制备方法。
• Novel bicyclic hydroxamates as inhibitors of histone deacetylase
  申请人：Leahy M Ellen

  公开号：US20060058553A1

  公开（公告）日：2006-03-16

  The present invention is directed to certain bicyclic hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed

  本发明涉及某些双环羟肟衍生物，它们是组蛋白去乙酰化酶的抑制剂，因此可以用于治疗与组蛋白去乙酰化酶活性相关的疾病。本发明还公开了制备这些化合物的制药组合物和过程。
• TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS
  申请人：Dax Scott

  公开号：US20090291979A1

  公开（公告）日：2009-11-26

  Disclosed are compounds, compositions and methods for treating various diseases and conditions, including pain. Such compounds are represented by Formula I as follows: wherein A, G, Y, R3, R4, and R5 are defined herein.

  本发明涉及用于治疗各种疾病和病症，包括疼痛的化合物、组合物和方法。这些化合物由以下式子I表示：其中A、G、Y、R3、R4和R5在此被定义。